Amryt Pharma gets US patent for headline drug

Amryt Pharma has been granted a US patent for its lead drug to be used as a treatment in the lucrative orphan disease market.

The development forms the next stage in the Dublin-listed company’s positioning of Episalvan as a world leading treatment for the rare skin disorder epidermolysis bullosa (EB), a hereditary condition that can be debilitating for sufferers but which currently has no available treatment.

The drug was initially set to be used as a treatment for partial-thickness wounds caused by a variety of things such as burns, skin grafts, and dermatological procedures — a use not, necessarily, off the table.